| |
| | Eloxatin Adjuvant Colon Cancer Trial: Design & Efficacy |
 | | Eloxatin, used in combination with infusional 5-FU/LV, is indicated for adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor. |
 | | Adjuvant treatment of stage III colon cancer patients who have undergone complete resection of the primary tumor. |
 | | The most common adverse reactions in patients with stage II or III colon cancer receiving adjuvant therapy were peripheral sensory neuropathy, neutropenia, thrombocytopenia, anemia, nausea, increase in transaminases and alkaline phosphatase, diarrhea, emesis, fatigue, and stomatitis. |
| www.eloxatin.com /hcp/about_eloxatin/adjuvant_colon_cancer_trial.aspx (1095 words) |
|